Sinovac Biotech Ltd (SVA) stock
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.47+0.00 (0.00%)
Close on Nov 13, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$0.83, down 165.4% from the year before. The highest annual figure on record is $113.44 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.83 | -165.4% |
| FY2024 | Dec 31, 2024 | $1.27 | – |
| FY2023 | Dec 31, 2023 | -$0.19 | -195.0% |
| FY2022 | Dec 31, 2022 | $0.20 | -99.8% |
| FY2021 | Dec 31, 2021 | $113.44 | +11594.8% |
| FY2020 | Dec 31, 2020 | $0.97 | +136.6% |
| FY2019 | Dec 31, 2019 | $0.41 | +20.6% |
| FY2018 | Dec 31, 2018 | $0.34 | -24.4% |
| FY2017 | Dec 31, 2017 | $0.45 | – |
| FY2016 | Dec 31, 2016 | -$0.01 | – |
| FY2015 | Dec 31, 2015 | -$0.03 | – |
| FY2014 | Dec 31, 2014 | -$0.03 | -123.1% |
| FY2013 | Dec 31, 2013 | $0.13 | – |
| FY2012 | Dec 31, 2012 | -$0.27 | – |
| FY2011 | Dec 31, 2011 | -$0.02 | – |
| FY2010 | Dec 31, 2010 | -$0.16 | -134.8% |
| FY2009 | Dec 31, 2009 | $0.46 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?